Compare IMNM & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | FRSX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 5.0M |
| IPO Year | 2020 | 2016 |
| Metric | IMNM | FRSX |
|---|---|---|
| Price | $24.87 | $1.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $32.80 | N/A |
| AVG Volume (30 Days) | ★ 951.9K | 32.4K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,941,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,127.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.93 | $0.78 |
| 52 Week High | $30.06 | $3.00 |
| Indicator | IMNM | FRSX |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 36.43 |
| Support Level | $19.28 | $1.06 |
| Resistance Level | $27.14 | $1.14 |
| Average True Range (ATR) | 1.08 | 0.09 |
| MACD | -0.48 | 0.00 |
| Stochastic Oscillator | 1.54 | 10.00 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.